Kieffer Tara Lynn, Chief Product Strategy Officer at Enanta Pharmaceuticals Inc. ($ENTA), made one open market sale of common shares in the last year, totaling nearly $30,000. Her most recent ENTA insider sale occurred on December 5, 2025. Among 11,678 insiders with open market sales, her activity ranks 10,827th by amount, well below the average of $8.6 million across about 6.4 transactions per insider. She reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 3257 | $14.25 | 33,925.0000 | 29,019,344 | 8.76% | 0.01% |
| Feb. 12, 2026 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 4987 | $0.00 | 37,182.0000 | 29,019,344 | 15.49% | 0.02% |
| Feb. 12, 2026 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 1575 | $0.00 | 32,195.0000 | 29,019,344 | 5.14% | 0.01% |
| Dec. 5, 2025 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 2106 | $14.23 | 30,620.0000 | 28,862,601 | 6.44% | 0.01% |
| Dec. 1, 2025 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 753 | $14.12 | 32,726.0000 | 28,862,601 | 2.25% | 0.00% |
| Nov. 25, 2025 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 28,862,601 | 9999.99% | 0.35% |
| Feb. 12, 2025 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 7500 | $0.00 | 36,805.0000 | 0 | 25.59% | 0.00% |
| Feb. 12, 2025 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 3326 | $5.59 | 33,479.0000 | 0 | 9.04% | 0.00% |
| Dec. 6, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 2283 | $8.06 | 29,305.0000 | 0 | 7.23% | 0.00% |
| Dec. 1, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 753 | $8.60 | 31,588.0000 | 0 | 2.33% | 0.00% |
| Nov. 27, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Stock Option (right to buy) | 81000 | $0.00 | 81,000.0000 | 0 | 9999.99% | 0.00% |
| June 17, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 7266 | $12.33 | 32,341.0000 | 0 | 18.35% | 0.00% |
| Feb. 12, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 973 | $12.41 | 39,607.0000 | 0 | 2.40% | 0.00% |
| Feb. 12, 2024 | ENANTA PHARMACEUTICALS INC | $ENTA | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 3320 | $0.00 | 40,580.0000 | 0 | 8.91% | 0.00% |